首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNA14 |
| Uniprot No | P01570 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-189aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSHMCNLSQTHSLNNRRTLMLMAQMRRIS PFSCLKDRHDFEFPQEEFDGNQFQKAQAISVLHEMMQQTFNLFSTKNSSA AWDETLLEKFYIELFQQMNDLEACVIQEVGVEETPLMNEDSILAVKKYFQ RITLYLMEKKYSPCAWEVVRAEIMRSLSFSTNLQKRLRRKD |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNA14重组蛋白的3篇代表性文献的简要概述(注：文献为模拟示例，实际研究可能有限)：
---
1. **文献名称**：*Cloning and Expression of Human IFNA14 Recombinant Protein in E. coli*
**作者**：Zhang L., et al.
**摘要**：本研究成功克隆了人IFNA14基因，并在大肠杆菌系统中实现重组表达。通过His标签纯化获得高纯度蛋白，体外实验证实其具有抗病毒活性，可抑制HepG2细胞中乙肝病毒复制。
2. **文献名称**：*Comparative Analysis of Antiviral Activity among Interferon Alpha Subtypes*
**作者**：Smith J.R., et al.
**摘要**：比较了包括IFNA14在内的12种干扰素α亚型重组蛋白的抗病毒效果。结果显示，IFNA14对丙肝病毒(HCV)的抑制作用较弱于IFNA2.但对特定免疫细胞的激活能力更显著。
3. **文献名称**：*Structural Characterization of IFNA14 and Its Receptor Binding Mechanism*
**作者**：Tanaka K., et al.
**摘要**：通过X射线晶体学解析了IFNA14重组蛋白的三维结构，揭示了其与干扰素受体IFNAR1/2结合的独特表位，为设计靶向IFNA14的免疫疗法提供结构基础。
---
**注意**：IFNA14作为干扰素α家族的非典型亚型，研究相对较少，实际文献可能需通过专业数据库(如PubMed)以“IFNA14 recombinant”或“Interferon alpha-14”为关键词检索最新成果。部分研究可能混合讨论多亚型，需仔细筛选。
**Background of IFNA14 Recombinant Protein**
Interferon alpha-14 (IFNA14) is a member of the type I interferon (IFN) family, a group of cytokines critical in mediating innate immune responses against viral infections and modulating adaptive immunity. Encoded by the *IFNA14* gene in humans, it shares structural homology with other IFN-α subtypes, characterized by a conserved α-helical structure and a core disulfide bond. IFNA14 signals through the heterodimeric IFN-α/β receptor (IFNAR), composed of IFNAR1 and IFNAR2 subunits, activating the JAK-STAT pathway to induce interferon-stimulated genes (ISGs) with antiviral, antiproliferative, and immunoregulatory functions.
Recombinant IFNA14 is produced using biotechnological platforms (e.g., *E. coli* or mammalian expression systems) to ensure high purity and bioactivity. Unlike native IFNA14. the recombinant form is often engineered with tags (e.g., His-tag) for simplified purification. Its production enables studies on subtype-specific interferon actions, as minor sequence variations among IFN-α subtypes can influence receptor binding affinity, signaling dynamics, and downstream effects.
Research on IFNA14 has highlighted its role in antiviral defense, particularly against hepatitis C virus (HCV) and herpesviruses, and its potential therapeutic applications in oncology and autoimmune diseases. For example, type I IFNs are used clinically to treat malignancies like melanoma and viral infections, though subtype-specific efficacy and toxicity profiles remain under investigation. IFNA14’s distinct activity in modulating immune cell functions (e.g., dendritic cell maturation, NK cell activation) also makes it a candidate for targeted immunotherapy.
Quality control of recombinant IFNA14 involves verifying molecular weight (~19-21 kDa), endotoxin levels, and bioactivity via cell-based assays (e.g., antiviral or STAT phosphorylation assays). Ongoing studies aim to optimize its clinical utility while minimizing side effects associated with broad IFN-α therapies.
×
